Biotech Buyout Binge Continues
For the second week in a row, buyout rumors and merger speculation sent a number of biotech and specialty pharmaceutical shares higher.
Ad Changes Ahead for Controversial Drugs
Ad executives and drug company officials say changes in advertising strategies are almost a certainty in the wake of the Vioxx and Celebrex news and new studies showing a consumer backlash.
Drug Patent Approvals
Newsletters alert you to new drug patent approvals.
U.N. Calls for Clone Ban
The United Nations has called on countries to ban all forms of human cloning “incompatable with human dignity.” The American religious right claims victory, but others say the declaration is the result of political maneuvering influenced by pressure from the United States.
Will California's Stem Cell Initiative Reap Royalties?
When the backers of California’s stem cell initiative were seeking voter support last year, they not only promised cures for dread diseases, but also licensing revenue for the state. A statement posted on the initiative proponents’ CuresforCalifornia.com Web site says that ‘California will benefit for decades from patents and royalties that result from the research.’ But most biotech IP lawyers say it is foolhardy and wildly optimistic to predict that royalty revenue will come to California in the uncertain area of stem cell-derived therapies.
Get updates by email
Editor
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
and Share
Reading
Translator
© Copyright - BiotechBlog — A thinkBiotech product
Recent Comments